GP consultation app launch met with some reservations

GP consultation app launch met with some reservations

November 10 2017 An app allowing patients to have an NHS consultation with GP using a smartphone...

ICO extends GDPR helpline with specific support for small organisations

ICO extends GDPR helpline with specific support for small organisations

November 6 2017 A dedicated helpline to support small organisations prepare for the General Data...

New document summaries data security and protection requirements for health and care services

New document summaries data security and protection requirements for health and care services

November 2 2017 New guidance on complying with the 10 data security standards recommended by the...

My Health Online system enhancements announced in Wales

My Health Online system enhancements announced in Wales

October 25 2017 The My Health Online (MHOL) system allowing patients to link to their GP practice...

EPS has saved prescribers £327 million

EPS has saved prescribers £327 million

October 13 2017 The Electronic Prescription Service saved £327 million for prescribers...

  • GP consultation app launch met with some reservations

    GP consultation app launch met with some reservations

    Friday, 10 November 2017 17:35
  • ICO extends GDPR helpline with specific support for small organisations

    ICO extends GDPR helpline with specific support for small organisations

    Monday, 06 November 2017 11:40
  • New document summaries data security and protection requirements for health and care services

    New document summaries data security and protection requirements for health and care services

    Thursday, 02 November 2017 16:34
  • My Health Online system enhancements announced in Wales

    My Health Online system enhancements announced in Wales

    Wednesday, 25 October 2017 15:33
  • EPS has saved prescribers £327 million

    EPS has saved prescribers £327 million

    Friday, 13 October 2017 10:03

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Management News

November 22 2017 The public and health professionals are being asked to consider reporting side effects from over the counter medicines via the Yellow Card scheme.
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...